Journal of Research in Medical Sciences

ORIGINAL ARTICLE
Year
: 2020  |  Volume : 25  |  Issue : 1  |  Page : 117-

Hypermethylation of dihydrofolate reductase promoter increases the risk of hypertension in Chinese


Guodong Xu1, Zhiyi Wang3, Lian Li3, Wenxia Li3, Jingcen Hu3, Shuyu Wang3, Hongxia Deng2, Bo Li3, Changyi Wang3, Zhishen Shen2, Liyuan Han4 
1 Medical Record Statistics Room, Ningbo Medical Center Lihuili Hospital; Department of Preventive Medicine, Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo University, Ningbo, Zhejiang, China
2 Department of Otorhinolaryngology Head and Neck Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, China
3 Department of Non-Communicable Disease Prevention and Control, Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen, Guangdong, China
4 Hwa Mei Hospital, University of Chinese Academy of Sciences; Department of Global Health, Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, Zhejiang, PR China

Correspondence Address:
Dr. Liyuan Han
Dr. Zhisen Shen, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang
PR China
Dr. Zhishen Shen
Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo
China

Background: DNA methylation was considered to play an important role in hypertension. However, the direct association between dihydrofolate reductase (DHFR) promoter methylation and hypertension remains unclear. We thus aimed to investigate the relationship between DNA methylation of DHFR promoter and hypertension. Materials and Methods: A total of 371 hypertensive patients (diastolic blood pressure ≥90 mmHg and/or systolic blood pressure ≥140 mmHg or a history of antihypertensive treatment) and 320 age- and sex-matched healthy controls from the Hypertension Management Information System in Nanshan Community Health Service Centers were included in this case–control study. Quantitative methylation-specific polymerase chain reaction was used to measure the level of DHFR promoter methylation, which was presented as the percentage of methylated reference (PMR). A multivariate logistic regression model was used to explore the risk of DHFR promoter methylation. Results: Our results indicated that the level of DHFR promoter methylation was higher in hypertensive patients (median PMR, 34.32%; interquartile range, 11.34–119.60) than in healthy controls (median PMR, 18.45%; interquartile range, 8.16–35.40) (P < 0.001). Multivariable analysis showed that the risk of DHFR promoter hypermethylation was significantly higher in hypertensive patients than in healthy controls (odds ratio = 3.94, 95% confidence interval = 2.56–6.02, P < 0.001). Furthermore, hypermethylation was positively associated with sex, high blood homocysteine levels, and alcohol drinking. In particular, the area under the receiver operating characteristic curve was 0.688 (0.585–0.668) for the male hypertensive patients, suggesting the potential diagnostic value of DHFR promoter methylation in male hypertension. Conclusion: Our results demonstrated that DHFR promoter hypermethylation is positively associated with the risk of hypertension in Chinese.


How to cite this article:
Xu G, Wang Z, Li L, Li W, Hu J, Wang S, Deng H, Li B, Wang C, Shen Z, Han L. Hypermethylation of dihydrofolate reductase promoter increases the risk of hypertension in Chinese.J Res Med Sci 2020;25:117-117


How to cite this URL:
Xu G, Wang Z, Li L, Li W, Hu J, Wang S, Deng H, Li B, Wang C, Shen Z, Han L. Hypermethylation of dihydrofolate reductase promoter increases the risk of hypertension in Chinese. J Res Med Sci [serial online] 2020 [cited 2021 Jan 28 ];25:117-117
Available from: https://www.jmsjournal.net/article.asp?issn=1735-1995;year=2020;volume=25;issue=1;spage=117;epage=117;aulast=Xu;type=0